Neuro-Ophthalmology Illustrated

Neuro-Ophthalmology Illustrated

by Valerie Biousse (Author), Nancy Newman (Author)

List Price: $119.99

Buy

Neuro-ophthalmology is an “overlap” specialty, encompassing all disorders that affect the parts of the central nervous system related to vision. Neuro-Ophthalmology Illustrated, Third Edition by world-renowned neuro-ophthalmologists and professors Valérie Biousse and Nancy J. Newman expands on the widely acclaimed prior editions, lauded with awards by the Association of American Publishers and the British Medical Association. The updated text reflects diagnostic advances such as optical coherence tomography and features new high-quality images and videos.

The text starts with neuro-ophthalmic and funduscopic examinations, visual fields, commonly used ancillary testing methods, and an overview of visual loss. Subsequent chapters detail a wide array of conditions including retinal vascular diseases, optic neuropathies, disc edema, disorders of higher cortical function, abnormal visual perceptions, diplopia, orbital syndromes, cavernous sinus and orbital vascular disorders, nystagmus/other ocular oscillations, and disorders of the eyelid. Final chapters are dedicated to nonorganic neuro-ophthalmic symptoms and signs, diagnosis of headache and facial pain, neurologic and systemic disorders that commonly have neuro-ophthalmologic manifestations, and an approach to management of the visually impaired patient.

Key Highlights

Concise text coupled with more than 600 high-quality images enhances understanding of complex concepts Easily accessible within pertinent sections, 69 video clips cover a wide spectrum of topics such as examination techniques, normal eye movements, eye movement disorders, and pupil findings Clinical pearls, flow charts, boxes, tables, and a highly detailed index at the end of the text improve retention and assimilation of knowledge This book is essential reading for students, ophthalmology, neurology, and neurosurgery residents, as well as seasoned clinicians in these specialties. At once authoritative and easy to read, this resource provides readers with all the tools they need to diagnose and manage neuro-ophthalmologic disorders.

This book includes complimentary access to a digital copy on https://medone.thieme.com.

NCT Neuro Master Match (N2M2) trial

The German National Center for Tumor Diseases (NCT) has developed a noncomparative screening trial called Neuro Master Match (N2M2) for first-line unmethylated glioblastoma classification.

The NCT Neuro Master Match (N2M2) trial is an open-label, multicenterphase 1/IIa umbrella trial for patients with newly diagnosed Glioblastoma IDH wildtype without MGMT promoter hypermethylation to show safety, feasibility, and preliminary efficacy of treatment with targeted compounds in addition to standard radiotherapy based on molecular characterization. N2M2 is formally divided into a Discovery and a Treatment part. Discovery includes broad molecular neuropathological diagnostics to detect predefined biomarkers for targeted treatments. Molecular diagnostics and bioinformatics are performed within 4 weeks, allowing a timely initiation of postoperative treatment. Stratification for Treatment takes place in 5 subtrials, including alectinibidasanutlinpalbociclibvismodegib, and temsirolimus as targeted therapies, according to the best matching molecular alteration. Patients without matching alterations are randomized between subtrials without strong biomarkers using atezolizumab and asinercept(APG101) and the standard of care, TMZ. For the phase I parts, a Bayesian criterion is used for continuous monitoring of toxicity. In the phase 2trials, progression-free survival at 6 months is used as endpoint for efficacy.

Molecular diagnostics and bioinformatic evaluation are performed within 4 weeks, allowing a timely initiation of postoperative treatment. Stratification for Treatment takes place in 5 subtrials, including alectinib, idasanutlin, palbociclib, vismodegib, and temsirolimus as targeted therapies, according to the best matching molecular alteration. Patients without matching alterations are randomized between subtrials without strong biomarkers using atezolizumab and asinercept (APG101) and the standard of care, TMZ. For the phase I parts, a Bayesian criterion is used for continuous monitoring of toxicity. In the phase II trials, progression-free survival at 6 months is used as endpoint for efficacy.

Molecularly informed trials may provide the basis for the development of predictive biomarkers and help to understand and select patient subgroups who will benefit 1).


The N2M2 study represents a significant advance in study design for evaluation of drugs in the early phase II space for newly diagnosed GBM. It will be of great interest to the field to see how this design plays out in “real life,” and whether any of the substudies show evidence of efficacy in their target populations. Furthermore, the practical experience of using extensive multiplatform biomarker data in a large, prospective platform study will aid other platform efforts in the field, including adaptive studies such as INSIGhT 2) 3) and GBM AGILE, 4) which target the later phase II and phase III areas of drug evaluation for both newly diagnosed and recurrent GBM 5).

References

1)

Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 2019 Jan 1;21(1):95-105. doi: 10.1093/neuonc/noy161. PubMed PMID: 30277538.
2)

Tanguturi SK, Trippa L, Ramkissoon SH, et al. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017;19(7):908–917.
3)

Colman H. Toward more informative biomarker-based clinical trials in glioblastoma. Neuro Oncol. 2017;19(7):880–881
4)

Alexander BM, Ba S, Berger MS, et al; GBM AGILE Network. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24(4):737–743.
5)

Colman H. A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. Neuro Oncol. 2019 Jan 1;21(1):6-7. doi: 10.1093/neuonc/noy190. PubMed PMID: 30590837.

Eso Masterclass In Neuro-Oncology: Multidisciplinary Management Of Adult Brain Tumour

September 20 — September 22

Milan, Italy

Programme

The European School of Oncology was founded by Umberto Veronesi and Laudomia Del Drago in 1982, with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment. By improving the skills of all health professionals dealing with cancer patients, ESO helps shorten the time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.

ESO’s mission is reflected in its motto “Learning to Care”, which emphasises the importance of the learning process, and the goal of caring for the patient in a holistic sense, in contrast to focusing purely on treating the disease.

Due to its financial independence, ESO has the rare privilege of being able to set its own priorities. It therefore pays particular attention to developing the transfer of knowledge in areas that are least supported by industry, such as surgery and in rare pathologies (including childhood tumours), and in countries and regions with limited economic resources.

WhatsApp WhatsApp us
%d bloggers like this: